Alnylam/Regeneron Face Crowded IgA Nephropathy Field, But Combinations Likely
Phase II data position cemdisiran well for Phase III, but several agents are already well ahead. However, Alnylam foresees a polypharmacy approach.
You may also be interested in...
Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Roche To Take Ionis Drug Forward Into Crowded Nephropathy Field
Roche is not disclosing Phase II results yet, but must exceed late-stage rival drug’s 50% reduction in protein build up to compete in immunoglobulin A nephropathy.
Four Major Clinical Trial Readouts To Watch Out For In Q2
Four prominent drug candidates are expecting topline mid- or late-stage data over the next few months. With the help of Biomedtracker's Q2 Outlook Report, we take a look at the assets that could help validate some of the companies developing them, from oncology to psychiatry.